Eisner Mark 4

What Happened

• Mark Eisner, a director of Jade Biosciences (JBIO), received a derivative award of 47,675 shares (transaction code A) on 2026-06-25. The award was reported at an acquisition price of $0.00, meaning no cash was paid by the insider at grant. This is a grant/compensation event, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-25; Filing date: 2026-06-26 (Form 4 accession 0001193125-26-286434).
• Shares granted: 47,675 (derivative award); reported acquisition price: $0.00.
• Vesting schedule (footnote): 1/36th of the total number of shares vests monthly following the grant date, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, cashless exercise, or tax withholding in the filing excerpt; filing appears timely.

Context

• This award is a typical equity-based compensation event for an insider. It does not involve an immediate purchase or sale of shares and therefore does not directly signal buying or selling sentiment.
• As the award vests monthly over three years (36 months), Eisner will only gain ownership of the shares gradually and subject to continued service to the company.